Yokkaichi, Japan

Kunihisa Baba

This inventor holds 1 USPTO granted patent. Top assignees: Sanwa Kagaku Kenkyusho Co., Ltd., Telik, Inc.. Active years: 2005.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kunihisa Baba. Retrieved from https://idiyas.com/inventor/kunihisa-baba

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 18.0

ph-index = 1

Forward Citations = 11(Granted Patents)


Company Filing History:


Years Active: 2005

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Kunihisa Baba: Innovating Healthcare with MCP-1 Antagonists

Introduction: Kunihisa Baba is a visionary inventor hailing from Yokkaichi, Japan, paving the way in the field of pharmacology with his groundbreaking patent on antagonists of MCP-1 function.

Latest Patents: Kunihisa Baba's notable patent centers around compounds that serve as antagonists of MCP-1 function, offering promising applications in the prevention and treatment of a range of inflammatory and autoimmune diseases like multiple sclerosis, as well as for allergic hypersensitivity disorders.

Career Highlights: With a keen focus on pharmaceutical innovation, Baba has made significant contributions while working with companies such as Telik, Inc. and Sanwa Kagaku Kenkyusho Co., Ltd.

Collaborations: Throughout his career, Kunihisa Baba has collaborated closely with esteemed coworkers like Edgardo Laborde and Louise Robinson, collectively driving forward the development of novel healthcare solutions.

Conclusion: Kunihisa Baba's dedication to advancing healthcare through his innovative inventions marks him as a trailblazer in the field, with his MCP-1 antagonist patent poised to make a lasting impact in the realm of medical treatment and care.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…